Keros Therapeutics Inc
NASDAQ:KROS

Watchlist Manager
Keros Therapeutics Inc Logo
Keros Therapeutics Inc
NASDAQ:KROS
Watchlist
Price: 12.74 USD 4.6% Market Closed
Market Cap: 516.7m USD

P/S
Price to Sales

145.5
Current
109.1
Median
6.5
Industry
Higher than median
Higher than industry value

Price to Sales (P/S) ratio is a valuation multiple that compares a company’s market capitalization to its revenues. It is an indicator of the value that financial markets have placed on each dollar of a company’s sales.

P/S
145.5
=
Market Cap
516.7m USD
/
Revenue
3.6m USD
Revenue Growth P/S to Growth
US
Keros Therapeutics Inc
NASDAQ:KROS
Average P/S: 3 182 765.7
145.5
69%
2.1
FR
Pharnext SCA
OTC:PNEXF
35 008 193.5
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.5
8%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.7
4%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
4.6
3%
1.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
11.7
10%
1.2
US
E
Epizyme Inc
F:EPE
2 012.4
N/A N/A
AU
CSL Ltd
ASX:CSL
4.8
7%
0.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
4.3
7%
0.6
US
S
Seagen Inc
F:SGT
19.4
30%
0.6
NL
argenx SE
XBRU:ARGX
16.3
37%
0.4

P/S Forward Multiples

Forward P/S multiple is a version of the P/S ratio that uses forecasted revenue for the P/S calculation. 1-Year, 2-Years, and 3-Years forwards use revenue forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/S
100.3
2-Years Forward
P/S
54.7
3-Years Forward
P/S
30

See Also

Summary
KROS intrinsic value, competitors valuation, and company profile.
DCF Valuation
KROS stock valuation using Discount Cash Flow valuation method.
Relative Valuation
KROS stock valuation using valuation multiples.
Wall Street Estimates
KROS price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
KROS stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 246,700+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.